Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Randomized Double-blind
100%
Ritonavir-boosted Darunavir
100%
Non-inferiority Trial
100%
Doravirine
100%
Antiretroviral Naïve
100%
Darunavir
60%
HIV-1 Infection
26%
Nucleoside Reverse Transcriptase Inhibitors
26%
Drug Dependence
13%
HIV RNA
13%
Non-inferiority
13%
Previously Untreated
13%
HIV Viral Load
13%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
13%
Efficacy Analysis
13%
Antiretroviral Therapy
6%
Adverse Events
6%
Nausea
6%
Treatment Group
6%
Once-daily
6%
Pharmacokinetic Profile
6%
In Vitro Activity
6%
One Dose
6%
Clinical Centers
6%
Treatment Options
6%
Serious Adverse Events
6%
Viral Infection
6%
U.S. Food
6%
Abacavir
6%
Ritonavir
6%
Emtricitabine
6%
Headache
6%
Treatment Difference
6%
Diarrhea
6%
Group Assignment
6%
Once-daily Dosing
6%
Funding Institutions
6%
Merck
6%
Response System
6%
Inhibitor Resistant
6%
Interactive Web Response
6%
Loss-to-follow-up
6%
Snapshot Algorithms
6%
Immunosuppressive Drugs
6%
Voice User Interface
6%
Lamivudine
6%
Drug Adverse Events
6%
Safety Analysis
6%
Acute Hepatitis
6%
Tenofovir
6%
Efficacy Endpoint
6%
Treatment-naive Adults with HIV
6%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Ritonavir
100%
Darunavir
100%
Doravirine
100%
Noninferiority Trial
100%
Human Immunodeficiency Virus 1 Infection
26%
Reverse-Transcriptase Inhibitor
26%
Adverse Event
20%
Nonnucleoside Reverse Transcriptase Inhibitor
13%
Pharmacokinetics
6%
Study Participant
6%
In Vitro
6%
Immunosuppressive Drug
6%
Abacavir
6%
Headache
6%
Diarrhea
6%
Virus Infection
6%
Nausea
6%
Emtricitabine
6%
Acute Hepatitis
6%
Lamivudine
6%
Acivicin
6%
Tenofovir
6%
Antiretroviral Therapy
6%
Alginic Acid
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Ritonavir
100%
Darunavir
100%
Noninferiority Trial
100%
Doravirine
100%
Human Immunodeficiency Virus 1 Infection
26%
RNA Directed DNA Polymerase Inhibitor
26%
Adverse Event
20%
Nonnucleoside Reverse Transcriptase Inhibitor
13%
Headache
6%
Nausea
6%
Immunosuppressive Agent
6%
Abacavir
6%
Emtricitabine
6%
Diarrhea
6%
Acivicin
6%
Virus Infection
6%
Lamivudine
6%
Tenofovir
6%
Acute Hepatitis
6%
Pharmacokinetics
6%
Alginic Acid
6%